Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer
I. V. Scholz(Ludwig-Maximilians-Universität München), Christine Spitzweg(Mayo Clinic), Konstantin Maletz(Ludwig-Maximilians-Universität München), Richard G. Vile(Mayo Clinic), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Neziha Cengic(Ludwig-Maximilians-Universität München), Elizabeth R. Bergert, James C. Morris(Clemson University), Burkhard Göke(Ludwig-Maximilians-Universität München), Claire Baker(Mayo Clinic)
Cited by 74
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Inhibition of Trypanosoma brucei Gene Expression by RNA Interference Using an Integratable Vector with Opposing T7 Promoters
|Journal of Biological Chemistry|2000|532
International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma
|Radiotherapy and Oncology|2017|374
Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement
|International Journal of Radiation Oncology*Biology*Physics|2020|211